Coagulation Factor XI – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) – Pipeline Review, H1 2020’, provides in depth analysis on Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Cardiovascular, Hematological Disorders and Infectious Disease under development targeting Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)

– The report reviews Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics and enlists all their major and minor projects

– The report assesses Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Anthos Therapeutics Inc

Aronora Inc

Bayer AG

Bio Products Laboratory Ltd

Bristol-Myers Squibb Co

Cambryn Biologics LLC

eXithera Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Jiangsu Hengrui Medicine Co Ltd

Mochida Pharmaceutical Co Ltd

Ono Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC

3.4.21.27) - Overview

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC

3.4.21.27) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC

3.4.21.27) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC

3.4.21.27) - Companies Involved in Therapeutics Development

Anthos Therapeutics Inc

Aronora Inc

Bayer AG

Bio Products Laboratory Ltd

Bristol-Myers Squibb Co

Cambryn Biologics LLC

eXithera Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Jiangsu Hengrui Medicine Co Ltd

Mochida Pharmaceutical Co Ltd

Ono Pharmaceutical Co Ltd

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC

3.4.21.27) - Drug Profiles

7300 Series - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AB-012 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AB-022 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

abelacimab [INN] - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-1831865 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-2433334 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-262084 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-654457 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-962212 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

coagulation factor XI (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

coagulation factor XI (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

coagulation factor XI (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EP-7041 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IONIS-FXILRx - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IONIS-FXIRx - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

milvexian - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MR-1007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONO-7269 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONO-7684 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

osocimab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHR-2285 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Factor XI for Bleeding And Clotting Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Factor XIa for Arterial Thrombosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC

3.4.21.27) - Dormant Products

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC

3.4.21.27) - Product Development Milestones

Featured News & Press Releases

Oct 28, 2019: Ionis Pharmaceuticals presents on its drug candidate IONIS-FXI-LRx at DIA/FDA Oligonucleotide Conference

Oct 09, 2019: Ionis' Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results

Nov 13, 2017: eXIthera Presents Clinical Data on Novel Small Molecule FXIa Inhibitor EP-7041 at American Heart Association

Jul 03, 2017: Bayer To Present Data on BAY 1213790 at ISTH 2017

Nov 01, 2016: Ionis Pharmaceuticals Reports Positive Phase 2 Data for IONIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis

Jul 04, 2016: MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial in Prevention of Thrombosis with Novel Antibody

Oct 30, 2015: Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis

Feb 24, 2015: Bayer HealthCare and Aronora Establish Partnership for the Pre-Clinical Manufacturing of AB-022

Dec 07, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery

Nov 18, 2014: Isis Pharmaceuticals To Host Webcast To Discuss ISIS-FXI Rx Data Presented At The ASH Annual Meeting

May 22, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx in the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery

May 22, 2014: Cambryn Biologics Receives From FDA Orphan Drug Designation For Human Factor XI

Apr 19, 2013: CML HealthCare's Subsidiary Hemostasis Reference Labs Receives Contract Extension From Isis Pharma

Oct 29, 2012: Isis Pharma Initiates Phase II Study Of ISIS-FXIRX In Patients Undergoing Knee Replacement Surgery

Dec 12, 2011: Isis Reports Positive Phase I Data Demonstrating ISIS-FXIRx Reduces Factor XI Activity Without Bleeding

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indication, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Investigation by Universities/Institutes, H1 2020

Products under Investigation by Universities/Institutes, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by Anthos Therapeutics Inc, H1 2020

Pipeline by Aronora Inc, H1 2020

Pipeline by Bayer AG, H1 2020

Pipeline by Bio Products Laboratory Ltd, H1 2020

Pipeline by Bristol-Myers Squibb Co, H1 2020

Pipeline by Cambryn Biologics LLC, H1 2020

Pipeline by eXithera Pharmaceuticals Inc, H1 2020

Pipeline by Ionis Pharmaceuticals Inc, H1 2020

Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020

Pipeline by Mochida Pharmaceutical Co Ltd, H1 2020

Pipeline by Ono Pharmaceutical Co Ltd, H1 2020

Dormant Projects, H1 2020

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports